Quest for the right Drug
מסטינון מחפיות 60 מ"ג MESTINON DRAGEES 60 MG (PYRIDOSTIGMINE BROMIDE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
דרז'ה : DRAGEE
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Pregnancy & Lactation : הריון/הנקה
4.6 Fertility, pregnancy and lactation Pregnancy There are insufficient data on the administration of Mestinon dragees 60 mg during pregnancy. In animal testing, pyridostigmine did not demonstrate any teratogenic effects following oral administration. However, at maternal toxic doses, foetotoxicity and effects on the offspring have been observed (see section 5.3). Pyridostigmine crosses the placental barrier. Since the severity of the disease can vary significantly in pregnant women, particular caution is required here in order to avoid a cholinergic crisis due to overdose. Therefore the use of Mestinon dragees 60 mg during pregnancy is permitted only if it is strictly indicated. The newborn should be monitored for possible effects. The i.v. administration of cholinesterase inhibitors can cause premature contractions in pregnancy. The risk of premature contractions is highest when used towards the end of pregnancy. It is not known whether there is a risk of premature contractions with oral use. Breastfeeding Small amounts of pyridostigmine have been found in the plasma of breast-fed newborns/children of women treated. Based on a very limited number of cases studied, no effects have been observed on breast-fed infants/children. If treatment is required, the infant should be monitored for possible effects or weaned. Fertility Animal studies did not demonstrate any effect on male or female fertility (see section 5.3).
שימוש לפי פנקס קופ''ח כללית 1994
Myasthenia gravis
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף
